Monopar Therapeutics Inc. , a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
52W Range
86thpctl
Volume
1.08×avg
Market Cap
749.56MUSD
P/E Ratio
-48.6TTM
Div Yield
-ann
Loading chart data...
Current StateState loading
Monopar Therapeutics Inc.
MNPRNASDAQ·USD·Closed
Monopar Therapeutics Inc.
MNPRNASDAQ·USD·Closed
$111.89
−1.80%
$111.89
−$2.05 (1.80%)
52W Range
86thpctl
Volume
1.08×avg
Mkt Cap
749.56MUSD
P/E
-48.6TTM
Div Yield
–ann
MNPR: Monopar Therapeutics Inc. Stock Analysis | finqOS
